SAN FRANCISCO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the third quarter ended September 30, 2018, on Wednesday, November 7, 2018, after NASDAQ market close.
UNITY will not conduct a conference call in conjunction with the financial results press release.
About UNITY
UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.
Investors
Endurance AdvisorsElizabeth Broderebroder@enduranceadvisors.com
Media
Austine GraffUNITY Biotechnology
707-593-6151
austine.graff@unitybiotechnology.com
Source: Unity Biotechnology, Inc.
